Metformin decreases angiogenesis via NF-κB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1
Open Access
- 4 May 2009
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 83 (3) , 566-574
Abstract
Polycystic ovary syndrome (PCOS) is associated with insulin resistance (IR), obesity, and cardiovascular complications. Thrombospondin-1 (TSP-1) is a novel antiangiogenic adipokine highly expressed in obese insulin-resistant subjects. We sought to assess TSP-1 levels in adipose tissue (AT) from PCOS women and matched controls. The effects of metformin treatment on circulating TSP-1 levels in PCOS subjects, the effects of serum from normal and PCOS women on in vitro migration and angiogenesis before and after metformin treatment, and ex vivo regulation of AT TSP-1 by D-glucose were also studied. Serum TSP-1 (ELISA), subcutaneous and omental AT TSP-1 mRNA (reverse transcriptase–polymerase chain reaction), and protein (western blotting) were significantly lower in PCOS women (P < 0.05). Corresponding plasminogen activator inhibitor-1 (PAI-1) and PAI-1 activity were significantly higher (P < 0.01). After 6 months of metformin treatment, there was a significant increase in serum TSP-1 (P < 0.05) and a corresponding decrease in PAI-1 and PAI-1 activity (P < 0.01). In vitro migration and angiogenesis were significantly increased in serum from PCOS women (P < 0.01); these effects were significantly attenuated by metformin treatment (P < 0.01) through the regulation of TSP-1 levels via nuclear factor-κB (NF-κB), extracellular regulated-signal kinase 1/2 (Erk1/2) and Erk5 pathways. Importantly, changes in the intima media thickness were predictive of changes in serum TSP-1 (P = 0.049). In AT explants, glucose significantly decreased TSP-1 protein production and secretion into conditioned media (ELISA) (P < 0.05, P < 0.001). TSP-1 levels are lower in PCOS women. Metformin treatment increases serum TSP-1 in these women. Our findings provide novel insights into the relationship between obesity, IR, and angiogenesis.Keywords
This publication has 20 references indexed in Scilit:
- Thrombospondin-1 Is an Adipokine Associated With Obesity, Adipose Inflammation, and Insulin ResistanceDiabetes, 2008
- Thrombospondin-based antiangiogenic therapyMicrovascular Research, 2007
- Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndromeThrombosis Research, 2005
- Adipose Tissue as an Endocrine OrganThe Journal of Clinical Endocrinology & Metabolism, 2004
- The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependentThe FASEB Journal, 2002
- Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.Diabetes, 2000
- Thrombospondin-1 Is a Major Activator of TGF-β1 In VivoCell, 1998
- Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosisDiabetologia, 1991
- Lipoprotein Lipid Concentrations and Cardiovascular Risk in Women with Polycystic Ovary SyndromeThe Journal of Clinical Endocrinology & Metabolism, 1985
- Immunohistochemical localisation of thrombospondin in human megakaryocytes and platelets.Journal of Clinical Pathology, 1983